XOMA Resumes; Drops 30% On Phase 2 Data (XOMA)

by Benzinga Staff
March 22, 2011 4:51 PM | 6 seconds read | Make a Comment
Loading...
Loading...
XOMA
XOMA
drops over 30% on poor phase 2 data for its clinical product.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In: NewsFDAMoversBiotechnologyHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!